---
document_datetime: 2025-12-12 11:07:40
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/azacitidine-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: azacitidine-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3699066
conversion_datetime: 2025-12-19 21:57:18.918362
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Azacitidine Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 12/12/2025                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000317191                                        | Update of section '6. Contents of the pack and other information' of the package leaflet to add in brackets the patient- friendly term for the pharmaceutical form used on small immediate packaging materials in line with QRD template v10.4 and update of the contact details of local representative.   |            |            |                        |
|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Article 61(3) / EMA/N/0000263471                        | - Notification acc. Article 61(3) - Accepted Update of the labelling to include the text \"cytotoxic\" in section '6. Other' under 'minimum particulars to appear on small immediate packaging units vial label'.                                                                                             | 25/04/2025 |            | Labelling              |
| Marketing Authorisation Transfer - H / EMA/T/0000247752 | - Transfer of a marketing authorisation - transfer of marketing authorisation from Mylan Ireland Limited to Mylan Pharmaceuticals Limited                                                                                                                                                                   | 14/02/2025 | 24/03/2025 | SmPC, Labelling and PL |